Skip to main content

Table 2 Clinical trials for MSLN-targeted therapies based on CAR-T therapy

From: Mesothelin as a biomarker for targeted therapy

NCT Number Title Status Interventions Phases Enrollment Start Date Locations
NCT03814447 The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer Not yet recruiting Drug: anti- MESO CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide Early Phase 1 10 2019-04-01 China
NCT03747965 Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors Recruiting Biological: Mesothelin-directed CAR-T cells Phase 1 10 2018-11-01 China
NCT03608618 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Recruiting Biological: MCY-M11 Phase 1 15 2018-08-27 United States
NCT03615313 PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor Recruiting Biological: PD-1 antibody expressing mesoCAR-T cells Phase 1/2 50 2018-08-06 China
NCT03638193 Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer Recruiting Biological: CART-meso cells Not Applicable 10 2018-07-11 China
NCT03545815 Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. Recruiting Biological: anti-mesothelin CAR-T cells Phase 1 10 2018-03-01 China
NCT03356808 Antigen-specific T Cells Against Lung Cancer Recruiting Biological: Lung cancer-specific T cells Phase 1/2 20 2017-12-15 China
NCT03356795 Intervention of CAR-T Against Cervical Cancer Recruiting Biological: Cervical cancer-specific CAR-T cells Phase 1/2 20 2017-11-15 China
NCT03497819 Autologous CARTmeso/19 Against Pancreatic Cancer Active, not recruiting Biological: CARTmeso CART19 Early Phase 1 10 2017-10-01 China
NCT03323944 CAR T Cell Immunotherapy for Pancreatic Cancer Recruiting Biological: huCART-meso cells Phase 1 18 2017-09-15 United States
NCT03198052 HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers Recruiting Biological: CAR-T cells targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, or CD80/86 Phase 1 30 2017-07-01 China
NCT03267173 Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. Recruiting Drug: Chimeric antigen receptor T cell Early Phase 1 10 2017-06-15 China
NCT03182803 CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor Recruiting Biological: CTLA-4/PD-1 antibodies expressing mesoCAR-T Phase 1/2 40 2017-06-07 China
NCT03054298 CAR T Cells in Mesothelin Expressing Cancers Recruiting Biological: huCART-meso cells Phase 1 30 2017-03-01 United States
NCT03030001 PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies Unknown status Biological: PD-1 antibody expressing mesothelin specific CAR-T cells Phase 1/2 40 2017-02-15 China
NCT02930993 Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors Recruiting Biological: anti-mesothelin CAR T cells Phase 1 20 2016-08-01 China
NCT02959151 A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy Unknown status Drug: CAR-T cell Phase 1/2 20 2016-07-01 China
NCT02792114 T-Cell Therapy for Advanced Breast Cancer Recruiting Drug: Cyclophosphamide; Biological: Mesothelin-targeted T cells; Drug: AP1903 Phase 1 36 2016-06-01 United States
NCT02706782 A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma Unknown status Drug: TAI-meso-CART Phase 1 30 2016-03-01 China
NCT02580747 Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso Unknown status Biological: anti-meso-CAR vector transduced T cells Phase 1 20 2015-10-01 China
NCT02414269 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Recruiting Genetic: iCasp9M28z T cell infusions; Drug: cyclophosphamide Phase 1 48 2015-05-01 United States
NCT02465983 Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer Completed Biological: CART-meso-19 T cells; Drug: Cyclophosphamide Phase 1 4 2015-05-01 United States
NCT02388828 CART-meso Long-term Follow-up Active, not recruiting Biological: lentiviral-based CART meso therapy   10 2015-03-01 United States
NCT02159716 CART-meso in Mesothelin Expressing Cancers Completed Biological: CART-meso Phase 1 19 2014-06-01 United States
NCT01897415 Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer Completed Biological: Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 Phase 1 16 2013-07-01 United States
NCT01583686 CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer Terminated Drug: Fludarabine; Biological: Anti-mesothelin CAR transduced PBL; Drug: Cycolphosphamide; Drug: Aldesleukin Phase 1/2 15 2012-05-04 United States
NCT01355965 Autologous Redirected RNA Meso-CIR T Cells Completed Biological: Autologous T cells Phase 1 18 2011-03-01 United States